<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00216034</url>
  </required_header>
  <id_info>
    <org_study_id>HKIT-GC</org_study_id>
    <nct_id>NCT00216034</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK</brief_title>
  <official_title>Randomized Multicenter Controlled Phase III Study of Postoperative Adjuvant Therapy for Stage II/IIIA Gastric Cancer Using TS-1 Alone or TS-1+PSK Combined Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hokuriku-Kinki Immunochemotherapy Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hokuriku-Kinki Immunochemotherapy Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled study is conducted on patients with resected gastric cancer assigned
      to postoperative adjuvant therapy of TS-1 alone or PSK combined with TS-1, with the objective
      to examine or validate the outcome, QOL and prognostic factors (host and tumor factors), and
      explore the factors enhancing the antitumor effect of TS-1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 5-year survival after gastric cancer surgery remains poor as the cancer advances to
      stages II, IIIA, IIIB and IV. Tegafur-gimeracil-oteracil potassium (TS-1) is used as the
      first line treatment for advanced and recurrent gastric cancer. But TS-1 is accompanied by an
      adverse drug reaction of bone marrow suppression that is not readily seen in conventional
      oral fluoropyrimidines. Among randomized controlled trials on postoperative adjuvant
      chemotherapy for gastric cancer, the beneficial results of survival rates using Krestin (PSK)
      in combination with chemotherapy have been reported. With the objective to enhance the
      antitumor effect of TS-1 and to improve the QOL of patients, we have planned to validate the
      clinical significance of combined PSK and TS-1 therapy as postoperative adjuvant therapy for
      gastric cancer, using in principle the TS-1 regimen of 2-week dosing 1-week off for 6 months
      followed by 2-week dosing 2-week off for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of recurrence (calculation of 3-year disease-free survival and overall survival rates)</measure>
    <time_frame>Five years after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relations of survival rate with compliance, postoperative complication, QOL, adverse events, recurrence status, and expression of immune or tumor markers</measure>
    <time_frame>Five years after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">255</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TS-1 Group: The group treated with TS-1 mono-therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TS-1+PSK Group: The group treated with combination therapy using TS-1 and PSK</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur-gimeracil-oteracil potassium (TS-1)</intervention_name>
    <description>From 4-8 weeks after surgery to 27-31 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 21 day cycle. Number of Cycles: 8 From 28-32 weeks after surgery to 53-57 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 28 day cycle. Number of Cycles: 7</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>TS-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Krestin (PSK)</intervention_name>
    <description>From 4-8 weeks after surgery to 53-57 weeks after surgery, 3 g/day, PO every day</description>
    <arm_group_label>2</arm_group_label>
    <other_name>PSK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with microscopic stage II or IIIA resectable gastric cancer

          -  Patients who have not received preoperative cancer therapy (radiotherapy, chemotherapy
             or immunotherapy)

          -  Patients with serum immunosuppressive acidic protein (IAP) measured within 2 weeks
             before surgery

          -  Patients with no metachronous or synchronous multiple cancer

          -  Patients without severe impairment of renal, hepatic and bone marrow functions

          -  Patients who are judged to be capable of tolerating surgery

          -  Patients with preoperative performance status 0 to 2

          -  Patients with no serious concurrent complications (such as bone marrow suppression,
             diarrhea and infection)

          -  Patients who are judged to be capable of tolerating this treatment, and who have given
             written informed consent to participate in this study

        Exclusion Criteria:

          -  Patients with fresh hemorrhage from the gastrointestinal tract

          -  Patients with retention of body fluid necessitating treatment

          -  Patients with infection, intestinal palsy or intestinal occlusion

          -  Patients who are pregnant or hope to become pregnant during the study period

          -  Patients with diabetes treated by continuous use of insulin or showing poor glycemic
             control

          -  Patients with a history of ischemic heart disease

          -  Patients with concurrent psychiatric disease or psychotic symptoms, and judged to have
             difficulties participating in the study

          -  Patients receiving continuous administration of steroids

          -  Patients who have experienced serious drug allergy in the past

          -  Others, patients judged by the investigator or subinvestigator to be inappropriate as
             subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koichi Miwa, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hokuriku-Kinki Immunochemotherapy Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Fukui Hospital</name>
      <address>
        <city>Eiheiji</city>
        <state>Fukui</state>
        <zip>910-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Fukui Hospital</name>
      <address>
        <city>Tsuruga</city>
        <state>Fukui</state>
        <zip>914-0195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shakaihoken Kobe Central Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>651-1145</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Central Hospital of Matto Ishikawa</name>
      <address>
        <city>Hakusan</city>
        <state>Ishikawa</state>
        <zip>924-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanazawa University Hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-0934</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ishikawa Prefectural Central Hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanazawa Redcross Hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>921-8162</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanazawa Medical University Hospital</name>
      <address>
        <city>Uchinada</city>
        <state>Ishikawa</state>
        <zip>920-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuchiyama City Hospital</name>
      <address>
        <city>Fukuchiyama</city>
        <state>Kyoto</state>
        <zip>620-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto Ohashi General Hospital</name>
      <address>
        <city>Fushimi</city>
        <state>Kyoto</state>
        <zip>612-8364</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houyu hospital</name>
      <address>
        <city>Joyo</city>
        <state>Kyoto</state>
        <zip>610-0121</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Maizuru Medical Center</name>
      <address>
        <city>Maizuru</city>
        <state>Kyoto</state>
        <zip>625-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Kyoto Hospital</name>
      <address>
        <city>Nagaokakyo</city>
        <state>Kyoto</state>
        <zip>617-0814</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantan General Hospital</name>
      <address>
        <city>Nantan</city>
        <state>Kyoto</state>
        <zip>629-0197</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rokujizo Hospital</name>
      <address>
        <city>Uji</city>
        <state>Kyoto</state>
        <zip>611-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Okamoto General Hospital</name>
      <address>
        <city>Uji</city>
        <state>Kyoto</state>
        <zip>611-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto Prefectural Yosanoumi Hospital</name>
      <address>
        <city>Yosano</city>
        <state>Kyoto</state>
        <zip>629-2261</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marutamachi Hospital</name>
      <address>
        <city>Nishinokyokurumazaka-cho</city>
        <state>Nakagyou-ku Kyoto</state>
        <zip>604-8405</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Asahi-machi</city>
        <state>Osaka Abeno-ku</state>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sumitomo Hospital</name>
      <address>
        <city>Nakanoshima</city>
        <state>Osaka Kita-ku</state>
        <zip>530-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsushita Memorial Hospital</name>
      <address>
        <city>Moriguchi</city>
        <state>Osaka</state>
        <zip>570-8540</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midorigaoka Hospital</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-1121</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiga University of Medical Science Hospital</name>
      <address>
        <city>Otsu</city>
        <state>Shiga</state>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Shigaken Hospital</name>
      <address>
        <city>Ritto</city>
        <state>Shiga</state>
        <zip>520-3040</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shimane University Hospital</name>
      <address>
        <city>Izumo</city>
        <state>Shimane</state>
        <zip>693-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Takaoka Hospital</name>
      <address>
        <city>Takaoka</city>
        <state>Toyama</state>
        <zip>933-8525</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kouseiren Takaoka Hoapital</name>
      <address>
        <city>Takaoka</city>
        <state>Toyama</state>
        <zip>933-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toyama Rosai Hospital</name>
      <address>
        <city>Uozu</city>
        <state>Toyama</state>
        <zip>937-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yatsuo General Hospital</name>
      <address>
        <city>Yatsuo</city>
        <state>Toyama</state>
        <zip>939-2376</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitade Hospital</name>
      <address>
        <city>Gobou</city>
        <state>Wakayama</state>
        <zip>644-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukui Cardio Vascular Center</name>
      <address>
        <city>Fukui</city>
        <zip>910-0833</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukui General Hospital</name>
      <address>
        <city>Fukui</city>
        <zip>910-8561</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukui Saiseikai Hospital</name>
      <address>
        <city>Fukui</city>
        <zip>918-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu Municipal Hospital</name>
      <address>
        <city>Gifu</city>
        <zip>500-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu Prefectural General Medical Center</name>
      <address>
        <city>Gifu</city>
        <zip>500-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu University Hospital</name>
      <address>
        <city>Gifu</city>
        <zip>501-1194</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nishijin Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8800</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto First Red Cross Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>605-0981</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nara City Hospital</name>
      <address>
        <city>Nara</city>
        <zip>630-8305</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Railway hospital</name>
      <address>
        <city>Osaka</city>
        <zip>545-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toyama Prefectural Central Hospital</name>
      <address>
        <city>Toyama</city>
        <zip>930-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet. 1994 May 7;343(8906):1122-6.</citation>
    <PMID>7910230</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>June 6, 2016</last_update_submitted>
  <last_update_submitted_qc>June 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hokuriku-Kinki Immunochemotherapy Study Group</investigator_affiliation>
    <investigator_full_name>Takashi Fujimura</investigator_full_name>
    <investigator_title>Assistant Professor of Gastroenterologic Surgery, Kanazawa University Hospital</investigator_title>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>TS-1</keyword>
  <keyword>PSK</keyword>
  <keyword>Disease-free survival</keyword>
  <keyword>Overall survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tegafur</mesh_term>
    <mesh_term>Krestin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

